About Umlaut.Bio
Umlaut.Bio is a spinout of the EMBL, is pursuing tRNA targets for treatment of cancer and immunological diseases.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Pre-Seed
Global Headquarters
Heidelberg, Germany
Tracked Since
Oct 2, 2026
Web & Domain Identity
Official Website
umlaut.bio
Domain Registered Date
May 13, 2022
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Company Profile
Company Milestones & Timeline
- Capital Raise
Pre-Seed announced
- Milestone
Website domain registered
umlaut.bio
Investors & Backers
Investor firms and individual backers were not publicly disclosed in available round filings for Umlaut.Bio.
Funding History
Pre-Seed equity
· Feb 20, 2026
Undisclosed
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026